Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UnitedHealth Plans “Series” Of Part D Formulary Restrictions In 2009

Executive Summary

National stand-alone Medicare drug plans co-sponsored by UnitedHealth and AARP will impose new formulary restrictions in major drug categories including cholesterol treatments, proton pump inhibitors and osteoporosis therapies in 2009 to help control costs

You may also be interested in...



Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits

The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes

Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits

The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes

Medicare Plans’ Formulary Restrictions Will Get More Scrutiny In 2010 Bids – CMS

The agency proposes that next year’s Part D bids report new drug utilization requirements in a clear and consistent way to make it easier to assess policy compliance.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel